Navigation Links
Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
Date:7/2/2012

so am pleased that, on the heels of this milestone, we are exploring the breadth of the CRLX101 opportunity by initiating additional studies in high priority target indications."

About CRLX101 
CRLX101 is an investigational anti-cancer agent that is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha.  CRLX101 is a dynamically tumor-targeted nanopharmaceutical designed to concentrate in tumors, prolonging drug exposure at the site of action.  Significant anti-tumor activity has been observed across a wide range of cancers in animal models.  CRLX101 is currently in Phase 2 clinical development.  More information on CRLX101 clinical studies can be found at www.clinicaltrials.gov.

About Cerulean Pharma Inc.
Cerulean Pharma Inc. is a clinical-stage company specializing in the development of dynamically tumor-targeted nanopharmaceuticals.  Cerulean is applying its proprietary nanopharmaceutical platform to advance a new class of therapeutic agents to address significant unmet medical needs.  With an initial focus in oncology, the Company's technology platform can be applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs.  Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, and CVF, LLC.  Cerulean is located in Cambridge, Massachusetts.  For more information, please visit the Company's website at http://www.ceruleanrx.com.

Media Contacts:

Schwartz MSL
Benjamin Navon/Kathy Vigneault
cerulean@schwartzmsl.com 
+1 781-684-0770


'/>"/>
SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. InnoPharma Completes $15 Million Series A Financing
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. MiMedx Group Completes $5,000,000 Private Placement
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. Auxogyn Completes $20 Million In Series A Funding
9. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
10. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
11. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... 15, 2014 ­ RedBrick Health , a fast-growing ... today announces that EmblemHealth , the ... is now providing the RedBrick Compass health assessment, combined ... all of its members. EmblemHealth is among the first ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2
... , ... by the Johns Hopkins University School of Medicine Still Available On-Demand,Four out of Five Attendees ... ... CardioCareLive , the live virtual congress presented by the Johns Hopkins University School of ...
... GUANGZHOU, China , June 3 /PRNewswire-Asia/ -- China ... a,manufacturer, leading distributor and developer of Western pharmaceuticals,traditional Chinese medicines ("TCM"), ... Stockholders (the "Annual,Meeting") held on May 27, 2010 . , ... ...
... -Proceeds to support acceleration of CYT387 Phase II myelofibrosis study- , ... MISSISSAUGA, ON , June 3 /PRNewswire-FirstCall/ ... approximately US$3.2 million through a non-brokered private placement of 2,500,000 common ... no discount to the closing price of the shares on the NYSE Amex ...
Cached Biology Technology:CardioCareLive, the Largest Online Cardiology Conference, Attracts 2,300 Attendees and Enjoys 92% Recommendation Rate 2CardioCareLive, the Largest Online Cardiology Conference, Attracts 2,300 Attendees and Enjoys 92% Recommendation Rate 3CardioCareLive, the Largest Online Cardiology Conference, Attracts 2,300 Attendees and Enjoys 92% Recommendation Rate 4CardioCareLive, the Largest Online Cardiology Conference, Attracts 2,300 Attendees and Enjoys 92% Recommendation Rate 5China Medicine Announces Results of Annual Meeting of Stockholders 2China Medicine Announces Results of Annual Meeting of Stockholders 3YM BioSciences raises US$3.2 million in support of JAK 1/2 program 2YM BioSciences raises US$3.2 million in support of JAK 1/2 program 3YM BioSciences raises US$3.2 million in support of JAK 1/2 program 4
(Date:4/24/2014)... Munich have identified the structural features that enable ... and endogenous RNAs in living cells. , When ... metabolism and hijack cellular resources for the production ... viral RNA molecules that are delivered directly to ... synthesized in the host cell, and provide the ...
(Date:4/24/2014)... study representing the largest study of animal intelligence to-date finds ... self-control. , Published this week in the journal Proceedings ... part of a long history of research aimed at understanding ... do things like make and use tools, read social cues, ... Until now, most studies of animal intelligence have focused on ...
(Date:4/24/2014)... new insights into the make-up of tropical forests, a ... have revealed unprecedented detail of the size, age and ... maps with hundreds of field plots. , The ... amount of carbon each tree can store. This is ... trees are given a cash value according to their ...
Breaking Biology News(10 mins):Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3Animals with bigger brains, broader diets have better self control 2Animals with bigger brains, broader diets have better self control 3Amazon rainforest survey could improve carbon offset schemes 2
... milk is the best source of food for infants. University ... second bestformula made from hazelnut oil. Casimir Akoh, ... in the College of Agricultural and Environmental Sciences, developed a ... structure of mother,s milk, which makes it better suited to ...
... helped biologists figure out why platelets, the cells that ... they are. Because platelets are important both for healing ... understanding of how they form and behave could have ... specific for blood clotting," said Alex Mogilner, professor of ...
... FRANCISCO May 25, 2012 -- Wells Fargo (NYSE:WFC) has ... Program a grant for $40,000 in support of marine ... the lack of engaging science education opportunities that inspire ... skills and adopt conservation attitudes and behaviors, and a ...
Cached Biology News:Hazelnuts improve infant formula 2Wells Fargo fosters environmental conservation through University of Miami's RJD program 2
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human OSCAR MAb (Clone 259501)...
Human/Mouse G9a/EHMT2 MAb (Clone A8620A) Keywords: Eu-HMTase2...
Human M-CSF...
Biology Products: